10-K: PACS Group Reports Strong 2025 Growth Amidst Legal Scrutiny

PACS Group, a leading post-acute healthcare provider, announced significant revenue and net income growth for 2025, while navigating multiple ongoing regulatory and legal investigations.

Summary

• Total revenue increased by 29.3% to $5.289 billion for the year ended December 31, 2025, up from $4.090 billion in 2024.
• Net income surged by 245.9% to $191.461 million in 2025, compared to $55.344 million in 2024.
• Adjusted EBITDA grew by 80.7% to $505.023 million in 2025, from $279.457 million in 2024.
• The company operates 321 post-acute care facilities across 17 states, serving over 31,700 patients daily.
• Mature facilities (purchased >36 months prior) achieved an average CMS Quality Measures (QM) Star rating of 4.4 Stars and an average occupancy rate of 95% in 2025.
• Skilled nursing services revenue increased by $1.164 billion, or 29.0%, driven by a 22.8% increase in patient days, primarily from acquisitions in late 2024 and 2025.
• Medicare and Medicaid accounted for 33.7% and 40.5% of routine revenue, respectively, in 2025.
• The company identified material weaknesses in its internal control over financial reporting for both 2024 and 2025, leading to a restatement of prior interim financial statements.
• Multiple ongoing regulatory investigations by the DOJ and an SEC investigation are examining potential violations of the False Claims Act, HIPAA, and issues related to accounting and internal controls.
• Securities class action and shareholder derivative lawsuits have been filed against the company and certain officers, alleging a scheme to inflate revenue and profitability.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with cautious optimism. While strong financial growth and superior quality metrics in mature facilities are positive, the ongoing material weaknesses in internal controls, multiple regulatory investigations, and securities litigation introduce significant uncertainty and potential liabilities, tempering overall sentiment.

Positives

• Total revenue increased by 29.3% to $5.289 billion in 2025, demonstrating strong top-line growth.
• Net income saw a substantial increase of 245.9% to $191.461 million in 2025, indicating improved profitability.
• Adjusted EBITDA grew by 80.7% to $505.023 million, reflecting enhanced operational performance.
• Mature facilities maintain high quality of care, with an average CMS QM Star rating of 4.4 Stars in 2025, significantly above the industry average of 3.5 Stars.
• Occupancy rates for Mature facilities reached 95% in 2025, well above the industry average of 79%, indicating strong demand and effective management.
• The company's disciplined acquisition strategy continues to drive growth, with 101 facilities acquired in late 2024 and throughout 2025.
• Average Medicaid rates increased by 5.2% in 2025 due to state reimbursement increases and participation in supplemental payment programs.
• Cash provided by operating activities increased by $36.9 million to $404.2 million in 2025, reflecting improved operational cash generation.

Negatives

• The company identified material weaknesses in its internal control over financial reporting for both 2024 and 2025, impacting the completeness and accuracy of revenue data and the control environment.
• The material weaknesses led to a restatement of previously issued interim financial statements for Q1 and Q2 2024.
• Multiple ongoing regulatory investigations by the U.S. Department of Justice (DOJ) and an SEC investigation are examining potential violations of the False Claims Act and HIPAA, and issues related to accounting and internal controls.
• A securities class action and shareholder derivative lawsuits have been filed, alleging a multi-year scheme to inflate revenue and profitability, which could result in significant legal costs and liabilities.
• Total facility occupancy slightly decreased year-over-year from 90.4% in 2024 to 89.1% in 2025, primarily due to lower occupancy in New and Ramping facilities following significant acquisitions.
• General and administrative expense increased by $71.3 million, or 20.7%, in 2025, largely due to an $87.3 million increase in legal and professional fees associated with investigations.
• The company's stock price experienced a significant decline in November 2024 following a short-seller report and has not fully recovered, leading to litigation.

Risks

• Dependence on third-party payors (Medicare, Medicaid) means changes in acuity mix, payor mix, payment methodologies, or cost containment initiatives could negatively impact revenue and financial condition.
• Risk of not being fully reimbursed for all services due to consolidated billing or bundled payments, potentially affecting revenue and financial results.
• Increased competition for, or a shortage of, nurses and other skilled personnel could raise staffing and labor costs and lead to monetary fines for non-compliance with staffing requirements.
• State efforts to regulate or deregulate the healthcare services industry or facility expansion could impair growth or increase competition.
• Failure to attract patients and residents or compete effectively with other healthcare providers could lead to declining revenue and profitability.
• Internal reviews may detect noncompliance, requiring reduced or repayment of billed amounts and other costs, potentially leading to False Claims Act liability.
• Significant risk of liability from litigation, including professional liability, patient abuse/neglect, elder abuse, wrongful death, and class action claims, which could result in substantial legal costs and damage awards.
• Material weaknesses in internal control over financial reporting could impair accurate and timely financial reporting, adversely affecting investor confidence and potentially leading to litigation or penalties.
• Inability to provide consistently high quality of care or employee misconduct could result in adverse business impacts, civil/criminal penalties, fines, or other actions.
• Significant reliance on information technology means any failure, inadequacy, or interruption of that technology could harm business operations and lead to security breaches and liability.
• Operational metrics are calculated using internal systems and tools and are not independently verified, and real or perceived inaccuracies could harm reputation and business.
• Inability to complete future facility or business acquisitions at attractive prices or successfully integrate them could adversely affect revenue and expected benefits.
• Difficulty completing partnerships that increase capacity consistent with growth strategy.
• Failure to achieve or maintain competitive quality of care ratings from CMS or private organizations could negatively affect business.
• Inability to obtain insurance or increased insurance costs could adversely affect business.
• Geographic concentration of facilities, particularly in California, makes the company vulnerable to economic downturns, regulatory changes, or natural disasters in those areas.
• Actions of national labor unions could adversely affect revenue and profitability through increased costs, contract delays, or strikes.
• Risks associated with leased real property, including lease termination, lease extensions, and special charges, could adversely affect business.
• Failure to generate sufficient cash flow to cover required payments or meet operating covenants under long-term debt, mortgages, and long-term leases could result in defaults and loss of facilities.
• Need for additional capital to fund operating subsidiaries and finance growth, which may not be available on acceptable terms or at all.
• Extensive and complex laws and government regulations (e.g., Anti-Kickback Statute, Stark Law, False Claims Act, HIPAA, OBBBA, staffing standards, ownership transparency) could require significant expenditures or operational changes and lead to penalties.
• Founders Jason Murray and Mark Hancock have substantial control (69.8% voting power), potentially leading to conflicts of interest with other stockholders and anti-takeover effects.
• Future sales, or the perception of future sales, of common stock by existing stockholders could cause the market price to decline.
• The company is subject to a securities class action litigation and derivative lawsuits, which are expensive, time-consuming, and could result in substantial damages or fines.
• Risk of delisting from the New York Stock Exchange if compliance with listing standards is not maintained.
• The market price of common stock may be volatile or decline steeply/suddenly regardless of operating performance, potentially resulting in substantial losses for stockholders.
• If estimates or judgments relating to critical accounting policies are based on incorrect assumptions, operating results could fall below expectations, leading to a decline in stock price.
• Non-U.S. Holders owning more than 5% of common stock may be subject to U.S. federal income tax on gain from sale or disposition if the company is deemed a USRPHC.
• Global economic and financial market conditions, including severe market disruptions, could impact business operations and demand for services.
• Acquisitions or investments in companies may divert management's attention, result in dilution, or fail to achieve expected benefits.
• The company may not be able to pay or maintain dividends, which would adversely affect its stock price.

Future Outlook

The company plans to continue its multi-faceted growth strategy by expanding its presence in existing and new markets through acquisitions and de-novo builds, leveraging operational upside in its current facilities by increasing occupancy and skilled mix, and growing its pipeline of leaders. It also intends to extract embedded value from real estate ownership and explore ancillary investment opportunities (PACS Ventures) in pharmacy, laboratory, transportation, and imaging services. Additionally, the company may expand into other post-acute sites of care like home health, hospice, and broader senior living communities. The company expects patient and resident service revenue to continue increasing as it executes its acquisition strategy.

Management Comments

• Our significant historical growth has been primarily driven by our expertise in acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care skilled nursing facilities.
• We believe our success is driven in significant part by our locally led, centrally supported operating model, through which we empower local leaders at each facility to operate their facility autonomously and deliver excellence in clinical quality and a superior experience for our patients.
• We believe that healthcare is local and we operate through a locally led, centrally supported model, recognizing that each patient, facility, and community is unique.
• We believe our model attracts high caliber, entrepreneurial professionals who value having considerable autonomy, accountability, and aligned incentives.
• Excellence in clinical quality and experience for our patients is at the forefront of our mission.
• We believe our current markets are attractive and that the states in which we operate each has unique benefits, such as favorable reimbursement dynamics, high barriers to entry, or population growth of adults aged 65 and older, which is our primary patient demographic.
• We anticipate that available acquisition opportunities will enable us to further penetrate our reach into these 17 states and to enter new states in the future.
• Real-estate ownership is a key component of our growth strategy as it can provide balance sheet support as an inflationary hedge, provide capital flexibility as a source of asset collateral, reduce the burden of leases and restrictive agreements, and provide us opportunities to create additional value in improving distressed assets.
• We believe our success in improving our acquired properties is reflected in the average QM Star rating, occupancy rate, and skilled mix by revenue for each of our Mature, Ramping and New facilities.
• Our culture of transparency across our regions and facilities fosters an environment where best-practices are shared among regions which promotes healthy competitiveness and constant improvement across our facilities.

Industry Context

StockSavvy.ai notes that PACS Group operates within a large and growing post-acute care industry, with CMS projecting total expenditures to reach $283.3 billion by 2031. The company's strategy of acquiring underperforming long-term custodial care SNFs and converting them to higher-acuity, short-term transitional care facilities aligns with the industry's shift towards value-based models and cost-effective care settings. The fragmented nature of the SNF industry, with many small operators facing regulatory and staffing pressures, presents ongoing acquisition opportunities for larger, well-managed providers like PACS Group. The increasing demand from an aging population and rising chronic conditions further supports the company's growth trajectory, despite a declining number of overall SNFs in recent years. However, the industry faces significant regulatory scrutiny, including new staffing standards (though temporarily repealed), ownership transparency rules, and ongoing government audits, which could impact all operators.

Comparison to Industry Standards

• PACS Group's average QM Star rating across its Mature facilities was 4.4 Stars as of December 31, 2025, significantly higher than the industry average of 3.5 Stars, indicating superior quality of care in its established facilities.
• The average occupancy rate for PACS Group's Mature facilities was 95% in 2025, substantially exceeding the industry average of 79%, demonstrating strong operational efficiency and patient demand.
• SNFs, including those operated by PACS Group, are positioned as the lowest-cost facility-based post-acute healthcare option, costing an average of $577 per covered day, compared to $1,957 for inpatient rehabilitation facilities and $1,788 for long-term acute care hospitals, according to MedPAC, highlighting the company's value proposition in the broader healthcare ecosystem.

Management Changes

Corporate Governance

Legal Proceedings

• On April 8, 2024, Providence Administrative Consulting Services and Paradise Valley Healthcare Center received a Civil Investigative Demand (CID) from the DOJ regarding an investigation into potential False Claims Act violations related to improperly induced patient referrals through remuneration in violation of the Anti-Kickback Statute.
• On September 11, 2024, the company received a CID from the DOJ regarding an investigation into its California-based skilled nursing facilities for potential False Claims Act violations related to submitting false claims to Medicare under the patient-driven payment model (PDPM).
• On September 30, 2024, Providence Group, Inc. received a CID from the DOJ regarding an investigation into its skilled nursing facilities, specifically Bishop Care Center, for potential False Claims Act violations related to submitting false claims to Medicare under the COVID-19 related Hospital Stay Waiver (1135 waiver).
• On February 26, 2025, the company received a subpoena from the DOJ Criminal Division per HIPAA, relating to an investigation into possible violations of 18 U.S.C. sections prohibiting fraudulent or false statements to the U.S. government, specifically concerning 1135 COVID Waiver practices, Medicare Part B billing for therapy services, insurance enrollment changes, cost waivers for co-pays/deductibles/co-insurance, and Medicare bad debt claims.
• The SEC's Division of Enforcement is conducting an investigation into matters related to the company's accounting, financial reporting, disclosure, and internal controls over financial reporting and disclosure controls.
• On November 13, 2024, a putative securities class action (Manchin v. PACS Group, Inc., et al.) was filed, alleging a multi-year scheme to inflate revenue and profitability by exploiting a COVID-era Medicare waiver, billing unnecessary Medicare Part B therapies, and falsifying licensure and staffing documentation. A consolidated complaint was filed on December 19, 2025, and defendants moved to dismiss on February 17, 2026.
• On February 14, 2025, a derivative action (Howard-Hines Action) was filed, alleging breach of fiduciary duties, unjust enrichment, waste of corporate assets, and contribution, based on similar allegations as the Manchin Action. This action was consolidated and stayed on June 9, 2025.
• On August 19, 2025, another derivative action (Boers v. Murray, et. al.) was filed with similar claims but was voluntarily dismissed on December 8, 2025, without prejudice.

Related Party Transactions

• The company had a Consulting and Strategic Advisory Services Agreement with Helios Consulting, LLC (owned by Jason Murray and Mark Hancock) for an annual cash consulting fee of $4.0 million, which was terminated as of December 31, 2024. The company paid $4.0 million in 2023 and $0 in 2024 and 2025.
• On March 24, 2023, Jason Murray and Mark Hancock each purchased 10,000 shares of the company's common stock for $0.001 per share in a private placement.
• The company's founders, Jason Murray and Mark Hancock, have provided personal guarantees under certain of the company's leases using their personal property, subjecting them to increased risk of default.

Stakeholder Impact

• Shareholders: Potential for increased value from strong revenue and net income growth, but significant risk from ongoing legal and regulatory investigations, material weaknesses in internal controls, and potential stock price volatility. Founders' substantial control may limit influence of other shareholders.
• Patients and Families: The company's focus on high-quality care and superior QM Star ratings for mature facilities suggests positive impact, but allegations in legal proceedings regarding false claims and quality of care could raise concerns.
• Employees: The company's 'employer-of-choice' model, training programs, and aligned compensation aim to attract and retain talent. However, labor shortages and potential union actions could impact working conditions and costs. Management changes in compliance and HR roles indicate efforts to strengthen internal support.
• Referring Providers: The company aims to be a preferred partner due to its ability to care for higher acuity patients and provide seamless transitions, which is beneficial for hospitals and other referral sources.
• Payors (Medicare, Medicaid, Managed Care): The company's high-value site of care and culture of compliance are intended to benefit payors, but ongoing investigations into false claims and billing practices could lead to increased scrutiny and potential recoupments or penalties.

Next Steps

• Continue to expand presence in existing and new markets through acquisitions and de-novo facility builds.
• Leverage operational upside within the existing footprint by driving higher occupancy and increasing skilled mix.
• Invest heavily in training existing leaders and expanding the bench of new administrators and RVPs to support future growth.
• Evaluate real estate purchase options to reduce rent burden and grow underlying earnings.
• Explore ancillary investment opportunities (PACS Ventures) such as pharmacy, laboratory, transportation, and imaging services.
• Evaluate opportunities to expand into other post-acute sites of care, including home health, hospice, and broader senior living communities.
• Continue remediation efforts for identified material weaknesses in internal control over financial reporting.
• Vigorously defend against ongoing DOJ and SEC investigations, as well as securities class action and shareholder derivative lawsuits.
• Monitor and advocate regarding future federal, state, and local regulatory changes, particularly those impacting Medicaid funding and staffing requirements.
• Deliver financial statements and a corresponding compliance certificate for the fiscal quarter ended June 30, 2026, to terminate the Liquidity Requirement under the Amended and Restated Credit Facility.

Key Dates

Keywords

Skilled Nursing Facilities, Post-Acute Care, Healthcare, SEC Filing, 10-K, Financial Performance, Acquisitions, CMS Star Rating, Occupancy Rate, Medicare, Medicaid, False Claims Act, HIPAA, Internal Controls, Material Weakness, Litigation, Corporate Governance, Stock Price Volatility, Regulatory Compliance, Long-term Care, Assisted Living, PACS Group